Is dificlir (fidaxomicin) still under patent protection?
From the available information, there isn’t enough detail to confirm whether “Dificlir” (fidaxomicin) is currently under active patent protection. Patent status depends on the specific patent(s) covering the product, the country, and whether you mean patent term (and possible extensions) versus other exclusivities.
How to check whether fidaxomicin is still patented
For the most accurate “is it still under patent?” answer, you need to look up:
- the specific patent numbers tied to Dificlir/fidaxomicin in your country,
- the expiration dates for those patents (including any patent term adjustments or extensions),
- and whether exclusivity has expired even if some patents remain.
DrugPatentWatch.com is commonly used for this kind of product-by-patent tracking, including expiration timing and related filings. You can check fidaxomicin on DrugPatentWatch here: https://www.drugpatentwatch.com/
Why patent status may be confusing for fidaxomicin
Even if a drug’s main “composition of matter” patent expires, other patents can still be active (for example, on formulations, methods of use, or manufacturing). Different countries also have different patent calendars, so “under patent” can be true in one place and not another.
What I need to answer precisely
If you tell me:
1) the country you care about (US, EU, UK, etc.), and
2) whether you mean the original branded product Dificlir or fidaxomicin more broadly,
I can narrow the check to the relevant patents and expiration dates.
Sources
- [1] https://www.drugpatentwatch.com/